跳至主要内容
临床试验/NCT00214916
NCT00214916Unknown2 期

KULeuven Intensive Insulin Study in Pediatric Intensive Care Patients

Greet Van den Berghe1 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2004年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
700
试验地点
1
主要终点
duration of dependency on intensive care (days in ICU)

研究概览

简要总结

In a previous study, the investigators showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality in adult intensive care patients. Whether this intervention also improves prognosis of pediatric intensive care patients remains unknown. The current prospective, randomized, controlled study will asses the impact of intensive insulin therapy on outcome of patients in a pediatric intensive care unit. On admission patients will be randomly assigned to either strict normalization of blood glucose according age adjusted values or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl to maintain blood glucose levels between 180-200 mg/dl.

详细描述

Study type: Interventional study

Study design: single centre, prospective, randomized, active control, parallel assignment, efficacy study

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
1 Day 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children admitted to the pediatric intensive care unit and anticipated to require intensive care for at least 24 hours

排除标准

  • Expected stay < 24 hours
  • Therapy restriction upon admission
  • No informed consent
  • Other study enrollment

研究组 & 干预措施

A

Active Comparator

conventional insulin therapy (using Actrapid IV)

干预措施: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia) (Drug)

B

Experimental

intensive insulin therapy (using actrapid IV)

干预措施: intensive insulin therapy (Actrapid IV to normoglycemia) (Drug)

结局指标

主要结局

duration of dependency on intensive care (days in ICU)

时间窗: time in ICU

Reduction of inflammation

时间窗: during ICU stay to day 5

次要结局

  • mortality (safety endpoint)(during time in ICU)
  • Duration mechanical ventilation(during time in ICU)
  • Organ failure/need for organ support(during time in ICU)
  • long-term follow-up study : focus on neurocognitive development (ethical approval granted)(3 years (+/- 6 months) after randomization)

研究者

发起方
Greet Van den Berghe
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Greet Van den Berghe

Head of Dept and laboratory of Intensive Care Medicine

KU Leuven

研究点 (1)

Loading locations...

相似试验

Tight Glycemic Control With Intensive Insulin... | 临床试验